Research

Study Type

Title of Study

Principal Investigators
Christina Charles-Schoeman, MD; Veena Ranganath, MD

For more information contact 310-825-0096 

Dietary Intervention on Rheumatoid Arthritis Assessed by Ultrasound in over weight patients

Status: Open for Enrollment

Principal Investigator

Veena K. Ranganath, MD, MS

For more information, please contact (310) 825-9956

Musculoskeletal Ultrasound Predicting Therapeutic Response in Tofacitinib in Rheumatoid Arthritis Patients

Status: Open for Enrollment

Principal Investigator

Veena K. Ranganath, MD, MS

For more information, contact (310) 825-9956

HDL (Carotid Study): Evaluation of HDL function in patients with and without Rheumatic Disease

Status: Open for Enrollment

Principal Investigator

Christina Charles, MD

For more information, contact Jeraldine Guzman (310) 825-4744

BMS: A Placebo-Controlled Study to Evaluate the Effect, Safety, and Characteristics of Abatacept in Subjects with Rheumatoid Arthritis with Hepatitis B.

Status: Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

Use of ACTHAR in Rheumatoid Arthritis Related Flares.

Status: Open for Enrollment

Principal Investigator

Veena K. Ranganath, MD, MS

For more information, contact (310) 825-9956

Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients with Dermatomyositis

Status: Open for Enrollment

 Principal Investigator

Christina Charles-Schoeman, MD

For more information, contact Jeraldine Guzman 
(310) 825-4744

Status: Open for Enrollment

For more information contact
Mia Vasquez-Gutierrez (310)825-6461

Rituximab plus Cyclophosphamide followed by Belimumab for the treatment of Lupus Nephritis (CALIBRATE)

Status: Open for Enrollment

For more information contact
Mia Vasquez-Gutierrez
310-825-6461

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (STOP RA)

Status: Open for Enrollment

Principal Investigators
Maureen McMahon, MD

For more information contact
Mia Vasquez-Gutierrez
310-825-6461

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with active Proliferative Lupus Nephritis

Status: Open for Enrollment

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating Efficacy and Safety of Anifrolumab in Adult subjects with Active Systemic Lupus Erythematosus (SLE)

Status: Open for Enrollment

Principal Investigator                                                           Jennifer Grossman, MD

For more information, contact Mia Vasquez-Gutierrez (310) 825-6461

Principal Investigator
Ram Raj Singh, MD

For more information contact
Ram Raj Singh, MD

Status: Open for Enrollment

Principal Investigator
Jennifer King, MD 

For more information contact
Jennifer King, MD 

Status: Open for Enrollment

Principal Investigator
Jennifer King, MD

For more information contact
Jennifer King, MD 

Principal Investigators
Jennifer Grossman, MD; Maureen McMahon, MD

For more information, contact Mia Vasquez-Gutierrez (310) 825-6461

 Psoriatic Arthritis

Novartis: CAIN457F2354 AIN457/Secukinumab (Cosentyx) for Active Psoriatic Arthritis.

Status: Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744

Status: Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

Blood and Skin Biopsy Donation: A research study to define the differences in Immune Responses in skin from patients with an autoimmune or inflammatory condition

Status:  Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact
Nashla Barroso
(310) 825-9682

Status: Open for Enrollment

Principal Investigators
Philip Clements, MD

For more information, contact Nashla Barroso (310) 825-9682

Quality of Life: Quality of Life of people with scleroderma: Health values and minimally important differences of people with scleroderma

Status: Open for Enrollment

Principal Investigator Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

BRAVOS ITN075AI: Study of an Investigational Drug, Brentuximab Vedotin, for Diffuse Cutaneous Systemic Sclerosis.

Status: Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

Cumberland: A Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.

Status: Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

GRASP: Genome Research in African American Scleroderma Patients (GRASP)

Status: Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744

SLS III: A Combination study of Pirfenidone (PFD) with Mycophenolate (MMF) for Treating Scleroderma-Related Lung Disease.

Status: Open for Enrollment

Principal Investigator
Sam Weigt, MD, Michael Roth, MD

Co-Investigator

Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682

STAT: Scleroderma Treatment with Autologous Transplant (STAT). A study of a Scleroderma Treatment Using the Patient's Own Blood Stem Cells.

Status: Open for Enrollment

Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744

Corbus JBT101-SSc-002: A phase 3 study to assess the safety and efficacy of Lenabasum in patients with Scleroderma. Lenabasum is an experimental drug that may reduce inflammation and stop the development of scar tissue (fibrosis) that results from chronic active inflammation. While there are no known treatments that can repair the damage already done, lenabasum may reduce or resolve disease symptoms and prevent further damage to tissue and organs in patients with chronic over-active inflammatory and fibrotic diseases such as scleroderma.

Status: Open for Enrollment

 Principal Investigator
Suzanne Kafaja, MD

For more information, contact Nashla Barroso (310) 825-9682 or Jeraldine Guzman (310) 825-4744

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Lay person title: Study of an Investigaional Treatment for ANCA Vasculitis

This is a clinical trial evaluating an investigational product called CCX168 (also known as Avacopan) in patients with  granulomatosis with polyangiitis (GPA, formerly called Wegener’s disease) and microscopic polyangiitis (MPA).

Status: Open for Enrollment

Tanaz Kermani, MD

For more information contact, Tandy Ramirez   310-206-0994

Clinical Transcriptomics in Systemic Vasculitis (CUTIS).

This is a multi-center study evaluating new ways to distinguish different forms of vasculitis that can affect the skin by evaluation of biopsy and laboratory testing.

Status: Open for Enrollment

Tanaz Kermani, MD (Rheumatology and Dr. Bonita Kozma (Dermatology)

For more information, contact Tandy Ramirez at 310-206-0994